People using popular drugs for weight loss, diabetes are more likely to be diagnosed with stomach paralysis, studies find CNNsource
AdvertisementSupported bylettersTo the Editor:Re “What a Year on Ozempic Taught Me,” by Johann Hari (Opinion guest essay, May 12):As an internal medicine physician for over 40 years, I am in…
Tom Lewis | January 9, 2013 Calculating pediatric drug dosages correctly is highly important as a minor mistake can have a significant implication for the patient.To help pediatricians and anaesthesiologists,…
AdvertisementSupported byThe company said it will work to remove content about drugs like Ozempic, extended fasting and more from the “For You” feed.By Talya MinsbergEmma Lembke did not know what…
With the recent popularity of glucagon-like peptide-1 (GLP-1) receptor agonists for treating type 2 diabetes and weight loss, scientists are examining the treatment possibilities of this class of medications for…
Steals & Deals: Up to 81% off Omaha steaks, Bluetooth speakers, more SectionsShowsMoreFollow todayMore BrandsAfter many years in the spotlight, Melissa McCarthy is used to people obsessing over her body,…
Roche says weight loss drug shows promising results in early trial CNBCsource
Leticia Carrillo says she’s tried just about everything to lose weight. “I tried different diets. I get bored. I just get bored,” Carrillo said. She’s also had a tummy tuck,…
People receiving weight-loss drug Wegovy (semaglutide) sustained weight loss for up to four years, shedding an average of 10% of their body weight during that time, a new study found.This…
Semaglutide — a glucagon-like peptide-1 (GLP-1) receptor agonist found in medications such as Ozempic, Rybelsus, and Wegovy — has dramatic benefits for people with obesity and other weight management issues,…